

- Legionella* spp. infections (Cont.):  
 community-acquired, 1015  
 diagnosis of  
 chest radiograph, 1016, 1017f  
 clinical cues, 1016f  
 collection and transport of specimens, 150e-5t  
 CT, 1016, 1018–1019f  
 laboratory tests, 1017, 1020t  
 nucleic acid tests, 150e-8, 1017  
 urinary antigen tests, 806, 1017  
 epidemiology of, 1015  
 etiology of, 1014–1015  
 extrapulmonary, 1016, 2198  
 hospital-acquired, 1015, 1020  
 pathogenesis of, 1015–1016  
 prevention of, 917–918, 1020  
 prognosis of, 1020  
 risk factors for, 805  
 in transplant recipients, 1015  
 treatment of, 1017, 1020t
- Legionnaire's disease. *See* *Legionella* spp. infections
- Leigh's syndrome, 85e-6, 85e-6t, 441e-40f, 462e-16
- Leiomyoma  
 small intestinal, 536  
 uterine, 596
- Leiomyosarcoma. *See also* Soft tissue sarcoma  
 gastric, 536  
 pathology of, 119e-1  
 small intestinal, 537  
 treatment of, 119e-2
- Leishmania* spp.  
 adherence of, 145e-3  
 characteristics of, 1387, 1388t  
 entry into host, 145e-1, 372e-22  
 epidemiology of, 1388t  
 geographic distribution of, 1388t  
*L. aethiops*, 1388t, 1393  
*L. braziliensis*, 245e-4t, 1388t, 1393  
*L. donovani*, 245e-4t, 1388t. *See also* Visceral leishmaniasis  
*L. guyanensis*, 1393  
*L. infantum*, 1388, 1388t  
*L. major*, 1388t, 1392, 1393  
*L. mexicana*, 1388t, 1392, 1393  
*L. tropica*, 245e-4t, 1388t, 1392  
 laboratory identification of, 245e-2, 245e-4t, 245e-6t  
 life-cycle hosts of, 245e-4t  
 life cycle of, 1387, 1388t
- Leishmania* spp. infections, **1387**  
 cutaneous  
 clinical features of, 152e-3t, 1392, 1392f  
 diagnosis of, 152e-3t, 245e-4t, 1392  
 differential diagnosis of, 1392  
 epidemiology of, 152e-3t, 1388t, 1389f, 1392  
 immunopathogenesis of, 1392  
 incubation period for, 152e-3t  
 prevention of, 152e-3t  
 in returning war veterans, 152e-3t, 152e-8  
 treatment of, 152e-3t, 152e-7, 1393  
 diffuse cutaneous, 1388t, 1393  
 epidemiology of, 152e-8, 245e-4t, 1387, 1388t, 1389f  
 mucosal, 1388t, 1393–1394, 1393f  
 prevention of, 1394  
 visceral. *See* Visceral leishmaniasis
- Lemierre's disease/syndrome  
 clinical features of, 233–234, 784, 1097  
 mortality from, 784  
 pathogenesis of, 231, 814, 1097  
 treatment of, 234
- LEMS. *See* Lambert-Eaton myasthenic syndrome (LEMS)
- Lenalidomide  
 action and targets of, 103e-19  
 adverse effects of, 671, 716–717  
 for amyloidosis, 722–723  
 for multiple myeloma, 716–717  
 for myelodysplasia, 671
- Lenègre disease, 1471t
- Length-biased sampling, 479, 509
- Lennox-Gastaut syndrome, 2544
- Lenticulus, 2514
- Lenticulostriate arteries, 2572
- Lentigo, 359, 360t
- Lentiviruses, 91e-1t, 91e-2, 225e-2, 1216, 1216f.  
*See also* HIV
- LEOPARD syndrome, 359, 360t
- LEP gene mutations, 415e-4t, 2364t
- Lepirudin, 728, 753–754, 753t, 754
- LEPr gene mutations, 415e-4t, 2364t
- Lepromatosis, diffuse, 1124
- Leprosy, **1122**  
 borderline, 1123t  
 clinical features of, 152e-6t, 1124–1125  
 cutaneous, 76e-11f, 357t, 829, 1123t, 1124f, 1125f  
 neuropathy, 2648, 2684  
 renal, 1836t, 1849  
 complications of, 228, 1125–1126  
 diagnosis of, 1126  
 differential diagnosis of, 1126  
 epidemiology of, 1123  
 global considerations in, 1123, 1124, 2684  
 incubation period for, 152e-6t, 1124  
 lepromatous, 76e-11f, 829, 1123t, 1124–1125, 1124f, 2684  
 multibacillary, 1127  
 paucibacillary, 1127  
 prevention and control of, 1128  
 reactional states in, 1125, 1125f, 1127–1128  
 in returning war veterans, 152e-6t  
 transmission of, 1123–1124  
 treatment of, 152e-6t, 2684  
 antimicrobial agents, 1126  
 reactions to, 1127–1128, 2684  
 regimens, 1126–1127, 1127t  
 tuberculoid, 357t, 359, 1123t, 1124, 1124f, 2684
- Leptin  
 actions of, 415e-3, 415e-3f  
 deficiency of, 2256  
 in hypogonadotropic hypogonadism, 336, 2364  
 in male pubertal development, 2357–2358  
 in obesity, 415e-4t, 415e-5  
 resistance to, 2450
- Leptin receptors, 415e-3, 415e-4f, 415e-4t
- Leptomeningeal metastases, 605, 606f
- Leptospira*/leptospirosis (Weil's syndrome), **1140**  
 clinical features of, 129t, 285, 908t, 1144  
 diagnosis of, 150e-1, 152e-2t, 772, 1144–1145  
 differential diagnosis of, 1145  
 epidemiology of, 1141–1142  
 etiologic agent of, 1140–1141, 1141f, 1142f  
 global considerations in, 1141–1142  
 incubation period for, 152e-2t, 1144  
 pathogenesis of, 1142–1143, 1143f, 1144f  
 prevention of, 152e-2t, 1145, 1145t  
 prognosis of, 1145  
 in returning war veterans, 152e-2t  
 treatment of, 152e-2t, 1145, 1145t
- Leriche's syndrome, 1642
- LES. *See* Lower esophageal sphincter (LES)
- Lesch-Nyhan syndrome, 431e-5
- Leser-Trelat sign, 359, 535
- Letermovir, 215e-9
- Lethal midline granuloma. *See* Extranodal NK/T-cell lymphoma, nasal type
- Letrozole, 103e-15, 337, 1795
- Leucine metabolism disorders, 434e-3t
- Leucovorin, 103e-11t, 103e-14  
 for colorectal cancer, 543  
 for gastric cancer, 535  
 for gestational trophoblastic disease, 124e-5, 597  
 for osteosarcoma, 119e-3  
 for pancreatic cancer, 556t  
 for PCP prophylaxis, 1251t, 1362t  
 for toxoplasmosis prophylaxis, 1251–1252t
- Leukapheresis, for CML, 694
- Leukemia  
 acute lymphoid. *See* Acute lymphoid leukemia (ALL)  
 acute myeloid. *See* Acute myeloid leukemia (AML)  
 acute promyelocytic. *See* Acute promyelocytic leukemia (APL)  
 adult T cell. *See* Adult T-cell leukemia/lymphoma  
 aggressive NK cell, 135e-3  
 chemotherapy-associated, 103e-8  
 chromosome abnormalities in, 102e-7  
 chronic eosinophilic, 135e-7–8, 135e-7t, 422, 672  
 chronic lymphoid. *See* B-cell chronic lymphoid leukemia (CLL)/small lymphocytic lymphoma  
 chronic myeloid. *See* Chronic myeloid leukemia (CML)  
 chronic neutrophilic, 135e-4–5, 135e-5t, 672  
 deaths from, 467t, 469f, 470t  
 definition of, 102e-1, 103e-1  
 gene therapy for, 91e-4  
 hairy cell. *See* Hairy cell leukemia  
 incidence of, 467t  
 infections in, 486  
 joint involvement in, 2247  
 late consequences of treatment, 623, 624t  
 mast cell, 2120  
 ocular invasion by, 206  
 oral manifestations of, 236, 237  
 paraneoplastic syndromes in, 612t  
 polycythemia vera and, 674  
 precursor B-cell lymphoblastic, 91e-4, 701  
 precursor T-cell lymphoblastic, 702t  
 splenomegaly in, 411  
 T-cell large granular lymphocytic, 135e-3  
 T-cell prolymphocytic, 135e-3  
 viruses and, 101e-7
- Leukemia cutis, 364t, 366
- Leukemia inhibitory factor, 372e-11t, 455
- Leukemic cell lysis pneumopathy, 1793
- Leukemoid reaction, 418–419
- Leukoarthritis (diffuse white matter disease), 174f, 2568, 2602
- Leukocidins, 145e-7
- Leukocyte(s), 62e-12f, 81e-1–2, 413. *See also* Basophil(s); Eosinophil(s); Lymphocyte(s); Monocyte(s); Neutrophil(s)
- Leukocyte adhesion deficiency (LAD)  
 cellular/molecular defects in, 419, 420t, 2106  
 clinical features of, 375e-1, 419, 420t  
 diagnosis of, 420t, 2106  
 subtypes of, 419, 420t  
 treatment of, 2106
- Leukocyte common antigen, 120e-2t
- Leukocyte esterase test, 865
- Leukocyte function-associated antigen (LFA-1), 372e-24t
- Leukocyte Ig-like receptor (LIR), 373e-4
- Leukocyte telomere length (LTL), 94e-3
- Leukocytoclastic (cutaneous small-vessel) vasculitis, 25e-11f, 76e-15f, 133t, 135, 364t, 368
- Leukoderma, 357, 357t, 358t, 359
- Leukodystrophy(ies), 432e-4t, 2608
- Leukoencephalopathy  
 progressive multifocal. *See* Progressive multifocal leukoencephalopathy (PML)  
 radiation therapy-related, 607  
 reversible posterior, 1793, 2568, 2584
- Leukoerythroblastosis, 671. *See also* Primary myelofibrosis
- Leukopenia. *See* Neutropenia
- Leukoplakia, 342f  
 hairy, 76e-9f, 240t  
 oral, 46e-3f, 76e-9f, 237, 240t, 342f, 477, 503  
 sublingual, 46e-2f
- Leukostasis, 1793
- Leukotrienes, 87, 372e-15t, 1746
- Leuprolide, 103e-15, 585, 2132